P-165 Efficacy and toxicity of FOLFIRI / aflibercept in second line colorectal cancer in real life population, retrospective study. Does first line matter?

Lignende værker

• Efficacy and safety of FOLFIRI/aflibercept in second‐line treatment of metastatic colorectal cancer in a real‐world population: Prognostic and predictive markers
  af: Fernández Montes, Ana, et al.
  Udgivet: (2019)
• Folfiri-Aflibercept vs. Folfiri-Bevacizumab as Second Line Treatment of RAS Mutated Metastatic Colorectal Cancer in Real Practice
  af: Ottaiano, Alessandro, et al.
  Udgivet: (2019)
• Efficacy and toxicity of aflibercept and bevacizumab in combination with FOLFIRI in second‑line therapy for metastatic colon cancer: a retrospective multicenter study
  af: M.   Yu. Fedyanin, et al.
  Udgivet: (2022-03-01)
• Phase II trial of aflibercept with FOLFIRI as a second‐line treatment for Japanese patients with metastatic colorectal cancer
  af: Denda, Tadamichi, et al.
  Udgivet: (2019)
• P-051 Preliminary clinical and pathologic characteristics of patients treated in second-line (2L) with 25 cycles (Cy) or more of FOLFIRI + Aflibercept (FA)
  af: Pericay, C., et al.
  Udgivet: (2016)